Authors: Seifirad S PMID: 32575019 PMCID: PMC7297676 DOI: 10.1016/j.mehy.2020.110005 Abstract Cytokine storm, multiorgan failure, and particularly acute respiratory distress syndrome (ARDS) is the leading cause of mortality and morbidity in patients with COVID-19. A fulminant ARDS kills the majority of COVID-19 victims. Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), is a novel anti-fibrotic agent with trivial adverse effects. Pirfenidone is [...]

Authors: Seifirad S PMID: 32575019 PMCID: PMC7297676 DOI: 10.1016/j.mehy.2020.110005 Abstract Cytokine storm, multiorgan failure, and particularly acute respiratory distress syndrome (ARDS) is the leading cause of mortality and morbidity in patients with COVID-19. A fulminant ARDS kills the majority of COVID-19 victims. Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), is a novel anti-fibrotic agent with trivial adverse effects. Pirfenidone is [...]

Authors: Saba A, Vaidya PJ, Chavhan VB, Achlerkar A, Leuppi J PMID: 32476885 PMCID: PMC7170064 DOI: 10.36141/svdld.v35i1.6393 Abstract There are no specific data on the management of pulmonary fibrosis post-H1N1 ARDS. We present the cases of three patients who responded positively to treatment with pirfenidone, azithromycin and prednisolone. Three males, aged 40, 45 and 59 [...]